Initiation of a fixed-dose four-factor prothrombin complex concentrate protocol.

Area of Science:

• Pharmacology
• Hematology
• Emergency Medicine

Background:

• Urgent warfarin reversal is critical for patients with bleeding or requiring surgery.
• Traditional four-factor prothrombin complex concentrate (4F-PCC) dosing relies on weight and initial INR.
• Variability in traditional dosing can lead to errors and delays in administration.

Purpose of the Study:

• To evaluate the efficacy and safety of a fixed-dose 4F-PCC strategy (1500 units) for urgent warfarin reversal.
• To determine the frequency of inadequate initial dosing requiring supplemental 4F-PCC.
• To assess the practicality and error rates associated with fixed-dose 4F-PCC administration.

Main Methods:

• Retrospective review of 63 patients receiving warfarin reversal with a fixed 1500-unit dose of 4F-PCC.
• Assessment of INR levels post-administration to identify patients eligible for supplemental dosing.
• Analysis of supplemental dose administration and reasons for not receiving it.

Main Results:

• 17% (11/63) of patients were eligible for supplemental 4F-PCC due to not achieving INR goals.
• Only 2 of the 11 eligible patients received a supplemental dose, both with initial INRs > 3.5.
• Most patients achieved target INR goals with the initial fixed dose, indicating adequate hemostasis.

Conclusions:

• A fixed 1500-unit dose of 4F-PCC is an effective and reasonable strategy for urgent warfarin reversal.
• This approach simplifies administration, reduces dosing errors, and allows for rapid delivery.
• Clinical judgment often guided decisions regarding supplemental dosing, suggesting perceived adequate hemostasis despite not meeting INR goals.